234 related articles for article (PubMed ID: 32614857)
1. The potential impact of human visceral leishmaniasis vaccines on population incidence.
Le Rutte EA; Coffeng LE; Malvolti S; Kaye PM; de Vlas SJ
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008468. PubMed ID: 32614857
[TBL] [Abstract][Full Text] [Related]
2. Inferring transmission trees to guide targeting of interventions against visceral leishmaniasis and post-kala-azar dermal leishmaniasis.
Chapman LAC; Spencer SEF; Pollington TM; Jewell CP; Mondal D; Alvar J; Hollingsworth TD; Cameron MM; Bern C; Medley GF
Proc Natl Acad Sci U S A; 2020 Oct; 117(41):25742-25750. PubMed ID: 32973088
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of eliminating visceral leishmaniasis from the Indian subcontinent: explorations with a set of deterministic age-structured transmission models.
Le Rutte EA; Coffeng LE; Bontje DM; Hasker EC; Postigo JA; Argaw D; Boelaert MC; De Vlas SJ
Parasit Vectors; 2016 Jan; 9():24. PubMed ID: 26787302
[TBL] [Abstract][Full Text] [Related]
4. Post kala-azar dermal leishmaniasis: A threat to elimination program.
Gedda MR; Singh B; Kumar D; Singh AK; Madhukar P; Upadhyay S; Singh OP; Sundar S
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008221. PubMed ID: 32614818
[TBL] [Abstract][Full Text] [Related]
5. A third generation vaccine for human visceral leishmaniasis and post kala azar dermal leishmaniasis: First-in-human trial of ChAd63-KH.
Osman M; Mistry A; Keding A; Gabe R; Cook E; Forrester S; Wiggins R; Di Marco S; Colloca S; Siani L; Cortese R; Smith DF; Aebischer T; Kaye PM; Lacey CJ
PLoS Negl Trop Dis; 2017 May; 11(5):e0005527. PubMed ID: 28498840
[TBL] [Abstract][Full Text] [Related]
6. Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased
Cloots K; Marino P; Burza S; Gill N; Boelaert M; Hasker E
Front Cell Infect Microbiol; 2021; 11():604117. PubMed ID: 33777831
[TBL] [Abstract][Full Text] [Related]
7. Quantifying the Infectiousness of Post-Kala-Azar Dermal Leishmaniasis Toward Sand Flies.
Mondal D; Bern C; Ghosh D; Rashid M; Molina R; Chowdhury R; Nath R; Ghosh P; Chapman LAC; Alim A; Bilbe G; Alvar J
Clin Infect Dis; 2019 Jul; 69(2):251-258. PubMed ID: 30357373
[TBL] [Abstract][Full Text] [Related]
8. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A; Singh VK; Tiwari R; Madhukar P; Rajneesh ; Kumar S; Gautam V; Engwerda C; Sundar S; Kumar R
Front Immunol; 2023; 14():1236952. PubMed ID: 37638047
[TBL] [Abstract][Full Text] [Related]
9. Policy Recommendations From Transmission Modeling for the Elimination of Visceral Leishmaniasis in the Indian Subcontinent.
Le Rutte EA; Chapman LAC; Coffeng LE; Ruiz-Postigo JA; Olliaro PL; Adams ER; Hasker EC; Boelaert MC; Hollingsworth TD; Medley GF; de Vlas SJ
Clin Infect Dis; 2018 Jun; 66(suppl_4):S301-S308. PubMed ID: 29860292
[TBL] [Abstract][Full Text] [Related]
10. Insights from mathematical modelling and quantitative analysis on the proposed WHO 2030 targets for visceral leishmaniasis on the Indian subcontinent.
NTD Modelling Consortium Visceral Leishmaniasis Group
Gates Open Res; 2019; 3():1651. PubMed ID: 32803128
[TBL] [Abstract][Full Text] [Related]
11. Post-Kala-Azar Dermal Leishmaniasis as a Reservoir for Visceral Leishmaniasis Transmission.
Le Rutte EA; Zijlstra EE; de Vlas SJ
Trends Parasitol; 2019 Aug; 35(8):590-592. PubMed ID: 31266711
[TBL] [Abstract][Full Text] [Related]
12. Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence.
Sundar S; Singh OP; Chakravarty J
Expert Rev Anti Infect Ther; 2018 Nov; 16(11):805-812. PubMed ID: 30289007
[TBL] [Abstract][Full Text] [Related]
13. The economic value of a visceral leishmaniasis vaccine in Bihar state, India.
Lee BY; Bacon KM; Shah M; Kitchen SB; Connor DL; Slayton RB
Am J Trop Med Hyg; 2012 Mar; 86(3):417-25. PubMed ID: 22403311
[TBL] [Abstract][Full Text] [Related]
14. Development of Leishmania vaccines in the era of visceral leishmaniasis elimination.
Engwerda CR; Matlashewski G
Trans R Soc Trop Med Hyg; 2015 Jul; 109(7):423-4. PubMed ID: 26048873
[TBL] [Abstract][Full Text] [Related]
15. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
16. Modelling spatiotemporal patterns of visceral leishmaniasis incidence in two endemic states in India using environment, bioclimatic and demographic data, 2013-2022.
Subramanian S; Maheswari RU; Prabavathy G; Khan MA; Brindha B; Srividya A; Kumar A; Rahi M; Nightingale ES; Medley GF; Cameron MM; Roy N; Jambulingam P
PLoS Negl Trop Dis; 2024 Feb; 18(2):e0011946. PubMed ID: 38315725
[TBL] [Abstract][Full Text] [Related]
17. Elimination of visceral leishmaniasis in the Indian subcontinent: a comparison of predictions from three transmission models.
Le Rutte EA; Chapman LAC; Coffeng LE; Jervis S; Hasker EC; Dwivedi S; Karthick M; Das A; Mahapatra T; Chaudhuri I; Boelaert MC; Medley GF; Srikantiah S; Hollingsworth TD; de Vlas SJ
Epidemics; 2017 Mar; 18():67-80. PubMed ID: 28279458
[TBL] [Abstract][Full Text] [Related]
18. Visceral leishmaniasis: An overview of vaccine adjuvants and their applications.
Ratnapriya S; Keerti ; Sahasrabuddhe AA; Dube A
Vaccine; 2019 Jun; 37(27):3505-3519. PubMed ID: 31103364
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Study of Transmission in Households with Visceral Leishmaniasis, Asymptomatic Infections and PKDL in Highly Endemic Villages in Bihar, India.
Das VN; Pandey RN; Siddiqui NA; Chapman LA; Kumar V; Pandey K; Matlashewski G; Das P
PLoS Negl Trop Dis; 2016 Dec; 10(12):e0005196. PubMed ID: 27974858
[TBL] [Abstract][Full Text] [Related]
20. Post-kala-azar dermal leishmaniasis: does it play a role in the transmission of Leishmania donovani in the Sudan?
El Hassan AM; Khalil EA
Trop Med Int Health; 2001 Sep; 6(9):743-4. PubMed ID: 11555443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
